Edition:
India

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

237.20CHF
5:06pm IST
Change (% chg)

CHF-1.40 (-0.59%)
Prev Close
CHF238.60
Open
CHF237.00
Day's High
CHF239.00
Day's Low
CHF237.00
Volume
9,176
Avg. Vol
25,831
52-wk High
CHF255.00
52-wk Low
CHF209.40

Latest Key Developments (Source: Significant Developments)

Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics
Tuesday, 28 Aug 2018 

Aug 27 (Reuters) - Affimed NV ::AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS.AFFIMED NV - TO RECEIVE $96 MILLION UPFRONT AND COMMITTED FUNDING AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $5.0 BILLION INCLUDING MILESTONE PAYMENTS.AFFIMED NV - ADDITIONAL $5.0 BILLION CO MAY RECEIVE ALSO INCLUDES ROYALTIES ON SALES.  Full Article

Genentech Says FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Genentech Inc::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR XOLAIR (OMALIZUMAB) FOR FOOD ALLERGIES.  Full Article

Hoffmann-La Roche Ltd - Health Canada Has Approved Hemlibra (Emicizumab Injection)
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Roche Holding AG ::HOFFMANN-LA ROCHE LIMITED - HEALTH CANADA HAS APPROVED HEMLIBRA (EMICIZUMAB INJECTION) FOR HEMOPHILIA A (CONGENITAL FACTOR VIII DEFICIENCY) PATIENTS.  Full Article

Puretech Health Announces Collaboration With Roche
Friday, 20 Jul 2018 

July 20 (Reuters) - PureTech Health PLC ::PURETECH HEALTH ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE TECHNOLOGY FOR ORAL ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES.PURETECH HEALTH PLC - PURETECH HEALTH TO RECEIVE UP TO $36 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT, AND EARLY PRECLINICAL MILESTONES.PURETECH HEALTH PLC - PURETECH HEALTH ALSO ELIGIBLE TO POTENTIALLY RECEIVE OVER $1 BILLION IN DEVELOPMENT MILESTONES.  Full Article

Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Celgene Corp ::ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY.CELGENE CORP - PHASE III IMPASSION130 STUDY, WHICH WAS SPONSORED BY ROCHE, MET ITS CO-PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.CELGENE - OVERALL SURVIVAL IS ENCOURAGING IN PD-L1 POSITIVE POPULATION AT INTERIM ANALYSIS, FOLLOW UP WILL CONTINUE UNTIL NEXT PLANNED ANALYSIS.CELGENE CORP - SAFETY IN TECENTRIQ PLUS ABRAXANE ARM APPEARED CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.CELGENE CORP - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH IN TECENTRIQ PLUS ABRAXANE COMBINATION.CELGENE CORP - DATA DEMONSTRATE POTENTIAL ROLE OF ABRAXANE AS PREFERRED CHEMOTHERAPY PARTNER FOR IMMUNOTHERAPY COMBINATIONS.  Full Article

Roche Diagnostics Formally Asks Health Canada To Review Its Harmony Test
Thursday, 28 Jun 2018 

June 27 (Reuters) - Roche Diagnostics::ROCHE DIAGNOSTICS SAYS HAS FORMALLY ASKED HEALTH CANADA TO REVIEW ITS HARMONY TEST, WHICH IS A BLOOD SCREENING TEST FOR PREGNANT WOMEN.  Full Article

PeptiDream announces expansion of discovery alliance with Genentech
Monday, 25 Jun 2018 

June 25 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today the expansion of its ongoing discovery and optimization collaboration with U.S.- based Genentech .  Full Article

FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
Friday, 8 Jun 2018 

June 8 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED ABBVIE & GENENTECH USA'S VENCLEXTA FOR TREATING PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA.  Full Article

Five Prime Therapeutics Announces Collaboration With Roche
Thursday, 31 May 2018 

May 30 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES.FIVE PRIME THERAPEUTICS INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED..  Full Article

Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis
Monday, 21 May 2018 

May 21 (Reuters) - :GENENTECH'S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION.  Full Article

RPT-FOCUS-Roche steps up efficiency drive to take sting out of biosimilars

LONDON/ZURICH, Sept 13 Roche, the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable.